FDA Brief

Warning letters Drugs

FDA warning letter to

Anhui Hanbon Daily Chemical Co., Ltd.

High riskIssued Aug 11, 2025Posted Aug 19, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.

What happened

FDA inspected the drug manufacturing facility from February 24 to 28, 2025. FDA found the company failed to adequately test incoming components, used an incorrect excipient in drug products, and used a component that exceeded a limit in the USP monograph. FDA also found inadequate test method validation, stability testing, and process validation.

What FDA found

  1. The company did not adequately test incoming components for identity or contamination and used an incorrect excipient in drug products.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The company released drug products without adequately validating its test methods to show they were accurate, sensitive, specific, and reproducible, or equivalent to USP methods.

    21 CFR 211.165(e)
  3. The company lacked an adequate stability program to support storage conditions and expiration dates.

    21 CFR 211.166(a)
  4. The company failed to adequately validate its manufacturing process before commercial distribution.

    21 CFR 211.100(a)

What FDA wants

FDA asks the company to correct the violations promptly and respond in writing within 15 working days with corrective actions and requested documentation; if it cannot complete them in that time, it must explain the delay and give a completion schedule. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC drugs from this contract manufacturer
  • distributors and importers of Chinese OTC drug products
  • quality teams qualifying raw material suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk